ArticleScientific reports2025
Increased plasma fibronectin mirrors intimal phenotypic switching of vascular smooth muscle cells in moyamoya arteriopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Impact of VEGFA rs2010963 on Bilaterality and Posterior Artery Stenosis in Patients with Moyamoya Disease.Translational stroke research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive stenosis of large intracranial arteries and formation of fragile collateral vessels that can be triggered by a broad range of genetic and immune factors. Central to MMD pathology is excessive proliferation of vascular smooth muscle cells (VSMCs) in the intima of affected arteries associated with contractile-to-synthetic phenotypic switching, but the underlying molecular mechanisms remain unclear. To identify dysregulated pathways we studied a cohort of 12 patients with well-documented MMD, including one post-mortem autopsy case, using a multi-omics approach combining whole exome sequencing with plasma proteomics. In addition, we conducted an in-depth spatial proteomics analysis of an occluded artery retrieved post-mortem from one idiopathic patient, combining targeted antibody-based imaging with laser capture microdissection coupled to mass spectrometry. Genetic predispositions for MMD was found in 8 out of 12 patients (67%), including three patients with variants in the major susceptibility gene RNF213 and five with varying underlying genetic conditions (trisomy 21, pathogenic variants in ACTA2, SAMHD1, NFIA). Artery spatial proteomics revealed phenotypic switching of vascular smooth muscle cells associated with infiltration of these cells in the intima, including loss of contractile and gain of synthetic marker proteins. Most notably, increased expression of cellular fibronectin in the occluded lesion was associated with increased levels in patients' plasma, providing a rationale for cellular fibronectin as potential tissue leakage biomarker for moyamoya disease. Finally, infiltration of macrophages and antigen-presenting cells in the intima pointed to a role for inflammatory signals in disease progression. Together, our data provide an unprecedented spatial view on protein changes in an occluded moyamoya artery, revealing intimal infiltration of synthetic vascular smooth muscle cells and antigen-presenting immune cells as key pathological findings, opening novel avenues for future diagnosis and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.